GNUV201 markedly reduced tumor growth enough to induce regression of tumor during the administration period in the B16F10 and Pan02 syngeneic model (Fig. 5b; 89% and 75% TGI, respectively). In order to compare anti-tumor efficacy with marketed antibodies, Keytruda® and Opdivo® which recognize only hPD-1, we used hPD-1 KI mice. This evidence concerns the gene PDCD1 and neoplasm.